Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | CASP6 | P55212 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.57 |
| ▸ | MYC | P01106 | 2/20 | 0.55 |
| ▸ | MAX | P61244 | 2/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TTR | P02766 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658490 | 1.00 | EP300 (0.61) | EP300HIF1ACASP6TSHRPDK1 | |
| SCHEMBL2550259 | 0.88 | PDK1 (0.72) | EP300HIF1ACASP6TSHRPDK1 | |
| SCHEMBL527425 | 0.86 | HCAR3 (0.55) | EP300HIF1ACASP6TSHRMYC | |
| SCHEMBL28107004 | 0.86 | MAPK1 (0.58) | EP300HIF1ATSHRPDK1MYC | |
| SCHEMBL1560385 | 0.85 | AR (0.58) | EP300HIF1APDK1MYCMAX | |
| SCHEMBL17775445 | 0.85 | PDK1 (0.54) | EP300HIF1ACASP6TSHRPDK1 | |
| SCHEMBL16392507 | 0.85 | PDK1 (0.54) | EP300HIF1ATSHRPDK1MYC | |
| SCHEMBL16974724 | 0.85 | CASP6 (0.63) | EP300HIF1ACASP6TSHRMYC | |
| SCHEMBL31003858 | 0.85 | CASP6 (0.63) | EP300HIF1ACASP6TSHRMYC | |
| SCHEMBL223878 | 0.83 | TTR (0.64) | CASP6TSHRMYCMAXHCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014260-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC (US) | 2026-01-15 | — | — | US | disclosed |
| WO-2023230059-A1 | MDM2 DEGRADER | NEWAVE PHARMACEUTICAL INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| CN-110997627-B | Cyst amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3672937-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| CN-110997627-A | Novel cystobacter amide derivatives | 亥姆霍兹感染研究中心有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
| EP-2598161-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | Amylin Pharmaceuticals, LLC (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012015975-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015975-A2 | GLP-1 RECEPTOR AGONIST COMPOUNDS HAVING STABILIZED REGIONS | AMYLIN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-8003785-B2 | Halo-substituted pyrimidodiazepines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2303889-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-24 | — | — | US | disclosed |
| WO-2009153197-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES AS PLKL INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| EP-1217434-A2 | Silver halide photographic element | EASTMAN KODAK COMPANY (US) | 2002-06-26 | — | — | EP | disclosed |
| EP-1217435-A1 | Silver halide photographic element and imaging process | EASTMAN KODAK COMPANY (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6361931-B1 | REACTIVITY, STABILITY | EASTMAN KODAK COMPANY | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | EP300 3960/4885HIF1A 1589/4885CASP6 1077/4885 |
| US-20260014260-A1 | MDM2 DEGRADER | MDM2, TP53, ADRM1 | EP300 4085/4885HIF1A 3690/4885CASP6 1328/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | EP300 4224/4885HIF1A 1978/4885CASP6 1090/4885 |
| US-20090318408-A1 | HALO-SUBSTITUTED PYRIMIDODIAZEPINES | PLK1, CCNI, CDK1 | EP300 472/4885HIF1A 4196/4885CASP6 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.